• Helpful online tools and downloadable, printable materials are available to you here. And in our FAQs, you’ll find answers to many frequently asked questions.

    • Mitigare<sup>®</sup> True Blue Savings Program

      Mitigare® True Blue Savings Program

      Eligible patients can receive Mitigare® free for 30 days and get $5 refills.

      Start Here
    • Gout Flare Questionnaire

      Gout Flare Questionnaire

      Use this printable form to talk with your doctor about your gout flares.

      DOCTOR VISIT FORM
    • Mitigare<sup>®</sup> Patient Brochure

      Mitigare® Patient Brochure

      Review the patient brochure to find out more about gout flares and Mitigare®.

      DOWNLOAD
    • Fill a Prescription

      Fill a Prescription

      Find out about convenient options for filling your Mitigare® prescription.

      FIND A PHARMACY
    • CompleteCare  Home Delivery Form

      CompleteCare Home Delivery Form

      Complete the form and bring it to your doctor to request Mitigare® home delivery.

      DOWNLOAD
    • Mitigare<sup>®</sup> Medguide

      Mitigare® Medguide

      Download a copy of our Medication Guide for important information.

      Download
    • Mitigare<sup>®</sup> Prescribing Information

      Mitigare® Prescribing Information

      Download a copy of the Mitigare® Prescribing Information PDF.

      Download

Go to All Resources

References

  1. Khanna D, Fitzgerald JD, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricem ia. Arthritis Care Res (Hoboken). Oct 2012;64(10):1431 - 1446.
  2. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis. Arthritis Care Res (Hoboken). 2012;64:1447-1451 and 1456-1459.
  3. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004 Dec;31(12):2429 - 2432.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.